Document Type : Original Article

Authors

Department of Biochemistry, Payame Noor university, Tehran, Iran

Abstract

Diabetes Type 2 is the most common type of diabetes, a common disorder of glucose homeostasis and accounts for 90% of cases. The prevalence of diabetes type 2 is increasing. Adenosine deaminase is an enzymatic polymorphism that plays an important role in modulating the biological activity of insulin. It seems that excessive activity of the adenosine A1 receptor has caused adiposity in diabetes type 2. In this study, we examined the correlation of ADA enzyme with diabetes type 2. This investigation was performed on 80 men and women between 40 and 80 years old in District 2 of Tehran with diabetes. Venous blood samples were collected after 12 hours of fasting blood was centrifuged. Then fasting blood glucose and HbA1c, Triglyceride, and total Cholesterol were measured for enzyme activity respectively by COBAS MIRA. Insulin was measured by ELISA and serum ADA enzyme activity was measured by photometry. The results of this study were done by SPSS software. A significant increase in serum ADA levels was observed in diabetic patients compared with the control group. A positive correlation was observed between ADA activity and FBS and HbA1c. The amount of HOMA-IR in diabetics was higher than in the control group, but no positive correlation was observed between serum levels of ADA and HOMA-IR. The enzyme adenosine deaminase can act as an immunological marker and the results of this study show that diabetes is associated with increased T cell activation markers and immune disequilibrium. Serum ADA level has a positive correlation with glycemic control status in patients.

Graphical Abstract

Increased levels of serum Adenosine deaminase (ADA) enzyme and increased risk of T cell activation markers in type 2 diabetes

Keywords

Main Subjects

Selected author of this article by journal

ِDr. Mahboobeh Talebi Mehrdar
Payame Noor university

ORCID

Google Scholar

Researchgate

Linked In

Open Access

This article is licensed under a CC BY License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: http://creativecommons.org/licenses/by/4.0/

 

Publisher’s Note

CMBR journal remains neutral with regard to jurisdictional claims in published maps and institutional afflictions.

 

Letters to Editor

Given that CMBR Journal's policy in accepting articles will be strict and will do its best to ensure that in addition to having the highest quality published articles, the published articles should have the least similarity (maximum 15%). Also, all the figures and tables in the article must be original and the copyright permission of images must be prepared by authors. However, some articles may have flaws and have passed the journal filter, which dear authors may find fault with. Therefore, the editor of the journal asks the authors, if they see an error in the published articles of the journal, to email the article information along with the documents to the journal office.

CMBR Journal welcomes letters to the editor ([email protected], [email protected]) for the post-publication discussions and corrections which allows debate post publication on its site, through the Letters to Editor. Critical letters can be sent to the journal editor as soon as the article is online. Following points are to be considering before sending the letters (comments) to the editor.

[1] Letters that include statements of statistics, facts, research, or theories should include appropriate references, although more than three are discouraged.

[2] Letters that are personal attacks on an author rather than thoughtful criticism of the author’s ideas will not be considered for publication.

[3] There is no limit to the number of words in a letter.

[4] Letter writers should include a statement at the beginning of the letter stating that it is being submitted either for publication or not.

[5] Anonymous letters will not be considered.

[6] Letter writers must include Name, Email Address, Affiliation, mobile phone number, and Comments.

[7] Letters will be answered as soon as possible.

  1. Aggarwal AN, Agarwal R, Sehgal IS, Dhooria S (2019) Adenosine deaminase for diagnosis of tuberculous pleural effusion: A systematic review and meta-analysis. PloS one 14 (3): e0213728. doi: https://doi.org/10.1371/journal.pone.0213728
  2. Alberti KGMM, Zimmet P, Shaw J (2007) International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabetic Medicine 24 (5): 451-463. doi: https://doi.org/10.1111/j.1464-5491.2007.02157.x
  3. Azeez SH, Jafar SN, Aziziaram Z, Fang L, Mawlood AH, Ercisli MF (2021) Insulin-producing cells from bone marrow stem cells versus injectable insulin for the treatment of rats with type I diabetes. Cell Mol Biomed Rep 1 (1): 42-51. doi: https://doi.org/10.55705/cmbr.2021.138888.1006
  4. Fazeli F, Ahanjan M (2022) The capacity of Stem Cells in Treatment of Diabetes. Cell Mol Biomed Rep 2 (4): 230-244. doi: Https://doi.org/10.55705/cmbr.2022.357066.1060
  5. Mirzaei AR, Shakoory-Moghadam V (2022) Bioinformatics analysis and pharmacological effect of Stevia rebaudiana in the prevention of type-2 diabetes. Cell Mol Biomed Rep: 64-73. doi: https://doi.org/10.55705/cmbr.2022.336232.1035
  6. Heseltine L, Webster JM, Taylor R (1995) Adenosine effects upon insulin action on lipolysis and glucose transport in human adipocytes. Molecular and cellular biochemistry 144: 147-151. doi: https://doi.org/10.1007/BF00944394
  7. Hoshino T, Yamada K, Masuoka K, Tsuboi I, Itoh K, Nonaka K, Oizumi K (1994) Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus. Diabetes Research and Clinical Practice 25 (2): 97-102. doi: https://doi.org/10.1016/0168-8227(94)90034-5
  8. Li Y, Raza F, Liu Y, Wei Y, Rong R, Zheng M, Yuan W, Su J, Qiu M, Li Y (2021) Clinical progress and advanced research of red blood cells based drug delivery system. Biomaterials 279: 121202. doi: https://doi.org/10.1016/j.jconrel.2021.01.014
  9. Keino D, Kondoh K, Kim Y, Sudo A, Ohyama R, Morimoto M, Nihira H, Izawa K, Iwaki-Egawa S, Mori T (2021) Successful treatment with cyclosporine and anti-tumour necrosis factor agent for deficiency of adenosine deaminase-2. Scandinavian Journal of Rheumatology 50 (3): 243-245. doi: https://doi.org/10.1080/03009742.2020.1772868
  10. Yegutkin GG (2021) Adenosine metabolism in the vascular system. Biochemical Pharmacology 187: 114373. doi: https://doi.org/10.1016/j.bcp.2020.114373
  11. Laaksonen DE, Lindstrom J, Lakka TA, Eriksson JG, Niskanen L, Wikstrom K, Aunola S, Keinänen-Kiukaanniemi S, Laakso M, Valle TT (2005) Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes 54 (1): 158-165. doi: https://doi.org/10.2337/diabetes.54.1.158
  12. Wang J, Wang Y, Chu Y, Li Z, Yu X, Huang Z, Xu J, Zheng L (2021) Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma. Journal of Hepatology 74 (3): 627-637. doi: https://doi.org/10.1016/j.jhep.2020.10.021
  13. Ma Y, Yu L, Zhang X, Xin C, Huang S, Bai L, Chen W, Gao R, Li J, Pan S (2018) Highly efficient and precise base editing by engineered dCas9-guide tRNA adenosine deaminase in rats. Cell Discovery 4 (1): 39. doi: https://doi.org/10.1038/s41421-018-0047-9
  14. Manjunath S, Sakhare PM (2009) Adenosine and adenosine receptors: Newer therapeutic perspective. Indian journal of pharmacology 41 (3): 97-105. doi: https://doi.org/10.4103%2F0253-7613.55202
  15. Su H, Liu T, Li Y, Fan Y, Wang B, Liu M, Hu G, Meng Z, Zhang Q (2021) Serum uric acid and its change with the risk of type 2 diabetes: A prospective study in China. Primary Care Diabetes 15 (6): 1002-1006. doi: https://doi.org/10.1016/j.pcd.2021.06.010
  16. Mokhtari M, Hashemi M, Yaghmaei M, Molashahi F, Shikhzadeh A, Niazi A, Ghavami S (2010) Serum adenosine deaminase activity in gestational diabetes mellitus and normal pregnancy. Archives of gynecology and obstetrics 281: 623-626. doi: https://doi.org/10.1007/s00404-009-1148-3
  17. Niraula A, Thapa S, Kunwar S, Lamsal M, Baral N, Maskey R (2018) Adenosine deaminase activity in type 2 diabetes mellitus: does it have any role? BMC endocrine disorders 18: 1-5. doi: https://doi.org/10.1186/s12902-018-0284-9
  18. Panjehpour M, Hemati S, Forghani MA (2012) Expression of A1 and A3 adenosine receptors in human breast tumors. Tumori Journal 98 (1): 137-141. doi: https://doi.org/10.1177/030089161209800119
  19. Pinelli NR, Hurren KM (2011) Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Annals of pharmacotherapy 45 (7-8): 850-860. doi: https://doi.org/10.1345/aph.1Q024
  20. Quinn L (2001) TYPE 2 DIABETES: Epidemiology, Pathophysiology, and Diagnosis. Nursing Clinics of North America 36 (2): 175-192. doi: https://doi.org/10.1016/S0029-6465(22)02543-9
  21. Dayani SB, Asgarbeik S, Asadi M, Amoli MM (2022) Adenosine deaminase gene variant in diabetes and obesity. Journal of diabetes and metabolic disorders 21 (1): 333-338. doi: https://doi.org/10.1007/s40200-022-00978-5
  22. Kelgandre DC, Pathak J, Patel S, Ingale P, Swain N (2016) Adenosine Deaminase - a Novel Diagnostic and Prognostic Biomarker for Oral Squamous Cell Carcinoma. Asian Pacific journal of cancer prevention : APJCP 17 (4): 1865-1868. doi: https://doi.org/10.7314/apjcp.2016.17.4.1865
  23. Attique H, Baig S, Ishtiaque S, Rehman R, Ahmed ST, Ali Shahid M (2022) Neuregulin 4 (NRG4) - the hormone with clinical significance in gestational diabetes mellitus. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 42 (6): 1931-1936. doi: https://doi.org/10.1080/01443615.2022.2054683
  24. Hashim ZR, Qasim QA, MH AL (2022) The Association of Serum Calcium and Vitamin D with Insulin Resistance and Beta-Cell Dysfunction among People with Type 2 Diabetes. Arch Razi Inst 77 (5): 1593-1600. doi: https://doi.org/10.22092/ari.2022.357641.2081
  25. Yin B, Ding L, Chen Z, Chen Y, Zhu B, Zhu Y (2023) Combining HbA1c and insulin resistance to assess the risk of gestational diabetes mellitus: A prospective cohort study. Diabetes Res Clin Pract 199: 110673. doi: https://doi.org/10.1016/j.diabres.2023.110673
  26. Jang HN, Yang YS, Lee SO, Oh TJ, Koo BK, Jung HS (2019) Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes. Endocrinology and metabolism (Seoul, Korea) 34 (4): 382-389. doi: https://doi.org/10.3803/EnM.2019.34.4.382
  27. Liang R, Yu L, Liu W, Dong C, Tan Q, Wang M, Ye Z, Zhang Y, Li M, Wang B, Feng X, Zhou M, Chen W (2022) Associations of bifenthrin exposure with glucose homeostasis and type 2 diabetes mellitus in a general Chinese population: Roles of protein carbonylation. Environmental pollution (Barking, Essex : 1987) 315: 120352. doi: https://doi.org/10.1016/j.envpol.2022.120352
  28. Lu CF, Ge XQ, Wang Y, Su JB, Wang XQ, Zhang DM, Xu F, Liu WS, Su M (2021) The relationship between adenosine deaminase and heart rate-corrected QT interval in type 2 diabetic patients. Endocr Connect 10 (8): 894-901. doi: https://doi.org/10.1530/ec-21-0199
  29. Vergès B (2005) New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes & Metabolism 31 (5): 429-439. doi: https://doi.org/10.1016/S1262-3636(07)70213-6
  30. Yasuda N, Inoue T, Horizoe T, Nagata K, Minami H, Kawata T, Hoshino Y, Harada H, Yoshikawa S, Asano O, Nagaoka J, Murakami M, Abe S, Kobayashi S, Tanaka I (2003) Functional characterization of the adenosine receptor contributing to glycogenolysis and gluconeogenesis in rat hepatocytes. European Journal of Pharmacology 459 (2): 159-166. doi: https://doi.org/10.1016/S0014-2999(02)02832-7
  31. Akwiwu E, Edem M, Akpotuzor J, Asemota E, Isong I (2021) Glycated Haemogloin, Fasting Plasma Glucose, Plasminogen Activator Inhibitor Type-1, and Soluble Thrombomodulin Levels in Patients with Type 2 Diabetes Mellitus. Nigerian journal of physiological sciences : official publication of the Physiological Society of Nigeria 36 (2): 159-164. doi: https://doi.org/10.54548/njps.v36i2.3
  32. Niraula A, Thapa S, Kunwar S, Lamsal M, Baral N, Maskey R (2018) Adenosine deaminase activity in type 2 diabetes mellitus: does it have any role? BMC Endocr Disord 18 (1): 58. doi: https://doi.org/10.1186/s12902-018-0284-9
  33. Dhas Y, Banerjee J, Mishra N (2020) Blood Viscosity, Glycemic Markers and Blood Pressure: A Study in Middle-Aged Normotensive and Hypertensive Type 2 Diabetics. Indian journal of clinical biochemistry : IJCB 35 (1): 102-108. doi: https://doi.org/10.1007/s12291-018-0798-y
  34. Kulkarni SV, Meenatchi S, Reeta R, Ramesh R, Srinivasan AR, Lenin C (2017) Association of Glycemic Status with Bone Turnover Markers in Type 2 Diabetes Mellitus. International journal of applied & basic medical research 7 (4): 247-251. doi: https://doi.org/10.4103/ijabmr.IJABMR_35_17